Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Atrial fibrillation (AF) is the most prevalent arrhythmia and is associated with an increased
risk of ischemic stroke (IS) and systemic embolism (SE). Stroke prevention is a key element …

Background: There is a plethora of real-world data on the safety and effectiveness of direct-
acting oral anticoagulants (DOACs); however, study heterogeneity has contributed to …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …

The novel oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban have been
recently indicated for stroke prevention in patients with atrial fibrillation (AF). Due to a lack of …